How does BPC-157 work?
BPC-157 is a synthetic pentadecapeptide, meaning a peptide of 15 amino acids, derived from a protective protein found in gastric juice (the acid and enzymes in the stomach). Predrag Sikirić's lab at the University of Zagreb isolated and characterized this form of peptide in the early 1990s. Most of what we know about how BPC-157 acts in the body comes from his group and close collaborators, along with a smaller but growing body of independent preclinical work.
The peptide's main role, as best as researchers can describe it, is to support tissue repair through several overlapping pathways. It promotes angiogenesis (the growth of new blood vessels supplying oxygen and nutrients to repair tissue) by increasing VEGF (vascular endothelial growth factor, which prompts new vessel growth). It also encourages fibroblasts (the cells that build connective tissue) to migrate into damaged areas and boost growth-hormone receptors on tendon cells, which may amplify the body's own repair (Chang et al., 2011; Chang et al., 2014).
What conditions is it used for?
Tendon and ligament injuries, including Achilles, rotator cuff, and tennis elbow
Post-surgical recovery for orthopedic and abdominal procedures
Inflammatory bowel issues and gut-lining repair
Muscle strains and sports injuries
Joint pain stemming from soft-tissue damage
Tendons and ligaments are notoriously slow to heal because they have limited blood supply. The most reproducible mechanism reported for BPC-157 is its angiogenic effect. It appears to push new vessels into the tissue where repair gets stuck. This framework is consistent with how peptide-prescribing physicians like Quinn Stillson, MD, describe the peptide's role in tendon and ligament injury.
What to expect during treatment
Before starting BPC-157, a clinician with a strong working knowledge of peptide therapy will take a detailed history regarding injury status, ask about cancer screening status, and confirm that a necessary foundation (sleep, protein, loading rehab, anti-inflammatory diet) to enhance optimal results with BPC-157 is in place. Cancer screening matters because BPC-157 promotes vessel growth. Active or undiagnosed cancers can increase along the same pathway. Most prescribers will not start a patient with an active malignancy or one who is overdue on age-appropriate screening. An example of age-appropriate screening that is overdue would be a 55-year-old who has never had a colonoscopy.
The most common route is a subcutaneous injection, just under the skin, the same way insulin is injected. Typical protocols run daily for four to eight weeks, often near the site of injury, with an oral form available for gut-focused use. Patients commonly report reduced pain and improved range of motion within the first two to three weeks. Clinicians track functional progress (range of motion, load tolerance, symptom diaries) and the patient’s overall statement of improvement, rather than blood biomarkers, since there is no validated lab test for the peptide's effect.
How BPC-157 Works (in depth)
The fuller picture of how BPC-157 acts in the body draws on three decades of mostly rodent research, with the Sikirić group providing the foundation and other labs filling in mechanism details. What follows is the working model, not a settled story.
In injured tissue, BPC-157 appears to help increase the body's normal repair sequence rather than introduce a new one. It increases VEGF expression and stabilizes nitric oxide signaling. This process allows the body to push more blood and oxygen toward the damaged area. BPC-157 also speeds the growth of fibroblasts from tendon explants and raises growth-hormone receptor expression on tendon cells. This creates more places for the body's own circulating growth hormone to land and work (Chang et al., 2011; Chang et al., 2014).
In the gut, BPC-157's protective effect on the stomach lining and intestinal wall is one of the most reproduced findings in the rodent literature. Models of NSAID-induced ulcers, colitis, and post-surgical bowel injury all show faster recovery across oral, subcutaneous, and intraperitoneal routes (Seiwerth et al., 2018). The peptide's acid resistance, traced to its origin in gastric juice, is likely why oral dosing works at all, which is unusual for a peptide of this size.
Two caveats matter. Most mechanism work comes from one lab and its close collaborators. The strongest claims have less independent replication than the volume of papers might suggest; and rodent biology does not automatically translate to human effect.
How BPC-157 Is Used in Practice
Clinicians who prescribe BPC-157 reach for it most often when standard rehab has stalled and a patient needs help moving repair forward.
Tendon and ligament injuries
These are the most common indications. Sports-medicine and integrative-medicine clinicians use BPC-157 for Achilles tendinopathy (chronic tendon damage and pain), rotator cuff strains, tennis elbow, and partial ligament tears that have not responded to eccentric loading or physical therapy. A typical protocol runs four to six weeks of daily subcutaneous injections, often near the affected joint, layered on top of a graded rehab program. Prescribers describe it as something they add to, not replace, the loading work that thickens tendons.
Post-surgical recovery
This is the second-most-common use, particularly after ACL reconstruction, meniscal repair, and rotator cuff surgery. Edwin Lee, a peptide-prescribing endocrinologist, has run open-label work with orthopedic surgeons injecting BPC-157 into the joint at closure, with patients reporting faster return to function. The protocol is short (two to four weeks) and timed to the early inflammatory phase.
Gut-lining repair
This uses the oral form, taken on an empty stomach for four to eight weeks. Practitioners use it for inflammatory bowel symptoms, post-antibiotic gut recovery, and NSAID-related gastric irritation, alongside foundational gut work.
Muscle strains and joint pain from soft-tissue damage
These follow the same daily-injection protocol as tendon use, covering low-grade strains, labral tears, meniscal injuries, and chronic patellar tendinopathy. Here, BPC-157 is often combined with PRP or used as a bridge between PRP sessions. See our related articles on PRP therapy and **shockwave therapy** for the wider regenerative options.
What the Evidence Supports
The most consistent positive findings sit at the cellular and animal-model level. In transected rat Achilles tendons, BPC-157 restored functional, biomechanical, and structural measures of healing and produced tendon-to-bone reattachment that does not occur spontaneously in untreated controls (Krivic et al., 2006). In rat medial collateral ligament models, the peptide produced consistent improvement across intraperitoneal, oral, and topical routes (Cerovecki et al., 2010). A 2019 review of the preclinical literature concluded that across the available animal studies, the musculoskeletal soft-tissue healing effect has been consistently reproduced, though largely within a single research group and its collaborators (Gwyer et al., 2019).
On the gut side, the strongest evidence covers NSAID-induced ulcers, anastomosis healing, and intestinal protection in colitis models (Seiwerth et al., 2018).
Human-side evidence is thin. A 2025 narrative review identified only a handful of small pilot studies in humans (covering intra-articular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics). The review concluded that clinical use is well ahead of the published trial base (McGuire et al., 2025). One trial in acute hamstring strain is currently recruiting on ClinicalTrials.gov. No completed randomized controlled trial in humans has been published.
Where the Evidence Is Limited
The most important critique of BPC-157 is structural. The strongest preclinical evidence comes from a single research group and its close collaborators, and the human RCT base is essentially absent. Nutrition researcher Layne Norton has argued that collagen peptides combined with resistance training have stronger published evidence for tendon thickness and function. Evidence-based physician Brad Stanfield makes a similar case, arguing that without human clinical trials, we cannot confirm safety or efficacy. He also states that patients are better served by interventions with stronger human evidence. Orthopedic surgeon David Geier frames it cautiously: the animal data is suggestive, but he wants to see more human studies before recommending the peptide.
Beyond the evidence gap, the long-term human safety profile is unknown. BPC-157 promotes angiogenesis and upregulates growth-factor pathways. Both are useful for healing tissue and potentially useful for tumor growth, which is why most peptide-prescribing physicians screen for active or precancerous disease before starting a patient. There are no published cases of BPC-157 causing or accelerating cancer, but the theoretical concern is legitimate, and long-term human surveillance data does not exist.
Safety and Regulation
BPC-157 is not FDA-approved for any indication. This means physicians who use it do so off-label (legal but not FDA-approved for that specific use). In 2023, the FDA placed BPC-157 in FDA 503A Category 2 (substances that raise significant safety risks), the regulatory category that lets compounding pharmacies (state-licensed pharmacies that make customized medications for individual patients) supply a substance without full drug-approval review. In 2024 the FDA issued warning letters to several compounding pharmacies. This led many to stop supplying it. Some still supply BPC-157 under specific medical-need exemptions.
The other pathway, the "research peptide" market (online suppliers selling product labeled "not for human use"), remains active but unregulated. Independent testing of those products has repeatedly found contamination and material that does not match the label. Anyone using BPC-157 should source through a licensed prescribing physician working with a 503A compounding pharmacy. World Anti-Doping Agency testing prohibits BPC-157 for competitive athletes under category S0 (substances with no approval for human therapeutic use); recreational athletes are not affected.
Common contraindications include active cancer, recent cancer diagnosis, pregnancy, lactation, and missed age-appropriate cancer screenings. Reported side effects in clinical use are uncommon and generally mild and include injection-site reactions, occasional rash, and mild stomach upset with the oral form.
The Future of BPC-157
Two threads of research are shaping where BPC-157 goes next. They include the move from case-series evidence toward registered controlled trials, and the regulatory contest over compounding-pharmacy access.
A small set of published human pilot studies, in intra-articular knee pain, interstitial cystitis, and intravenous safety, has produced encouraging but very preliminary signals. A larger registered trial in acute hamstring strain is now recruiting. Any randomized controlled data that emerges from these will be the first peer-reviewed human evidence beyond pilot-series level. This trial will substantially clarify whether the rodent findings have the same effect on humans. On the regulatory front, peptide-prescribing physician groups and patient advocacy organizations are engaged with the FDA on the 503A bulk-substances pathway. The outcome over the next two to three years will determine whether US patients can continue to access pharmaceutical-grade material through compounding pharmacies.
In clinical practice, the most likely near-term development is the formalization of combination protocols, particularly BPC-157 alongside PRP, prolotherapy, and shockwave therapy. Published outcome data is needed and would help produce reliable evidence that supports the use of BPC-157 in humans.
Takeaway
BPC-157 sits in an unusual spot in regenerative medicine. The preclinical evidence is among the deepest of any peptide in current clinical use, with a large body of rodent studies, a reasonably well-characterized mechanism, and roughly a decade of off-label clinical experience among peptide-prescribing physicians with a generally favorable safety profile. However, the human RCT base, by contrast, is thinner than for almost any peer treatment, and regulatory access has tightened materially since 2023\.
The mechanism story is well-characterized, and the peptide-prescribing community has accumulated meaningful pattern recognition about what BPC-157 helps and what it does not. But the formal human evidence is limited, with source quality a live concern.
If you decide to try it, work with a licensed prescribing physician who can source pharmaceutical-grade material from a 503A compounding pharmacy and avoid the "research peptide" online market entirely. Be up to date on age-appropriate cancer screening before you start. Time the course to a specific injury or post-surgical window rather than continuous indefinite use, and check in every two to three weeks to confirm functional progress.
If you’re looking for a provider, you can browse vetted BPC-157 clinics across the U.S. in our directory.
